Melisi, Davide
Garcia-Carbonero, Rocio
Macarulla, Teresa
Pezet, Denis
Deplanque, Gael
Fuchs, Martin
Trojan, Jorg
Oettle, Helmut
Kozloff, Mark
Cleverly, Ann
Smith, Claire
Estrem, Shawn T.
Gueorguieva, Ivelina
Lahn, Michael M. F.
Blunt, Al
Benhadji, Karim A.
Tabernero, Josep
Article History
Received: 21 May 2018
Revised: 14 July 2018
Accepted: 3 August 2018
First Online: 15 October 2018
Availability of data and materials
: All data generated during the study is available at Eli Lilly.
: The data from this study were presented in part at ASCO 2013, AACR2016 and ASCO 2016.
: The study was conducted according to the principles of good clinical practice, applicable laws and regulations, the Council for International Organisations of Medical Sciences International Ethical Guidelines, and the Declaration of Helsinki. Each institution’s ethical review board approved the study. All patients signed an informed consent document before study participation.
: D.M. reports research funding from Shire, Incyte, and Celgene; a consulting role with Eli Lilly, Shire, Baxter and Incyte. G.D. reports research funding from Bavarian Nordici, Genentech, Janssen-Cilag, Roche, Sanofi, Eli Lilly, Exelixis, Sotio and Merck Serono; and travel fees from Roche, Amgen and Sanofi. M.F. reports a consulting role with Eli Lilly. J.T. reports a consulting role with Eli Lilly; speakers’ bureau from Bayer, Amgen and Merck Serono; and travel fees from Bayer. M.K. reports honorarium from Eli Lilly, Genentech, and Roche; a consulting role with Eli Lilly, Genentech, and Roche; and speakers’ bureau from Eli Lilly during the conduct of the study, Genentech, and Roche. A.C., C.S., S.T.E., I.G. and K.A.B. are all current employees and stockholders of Eli Lilly; M.M.F.L. is a former employee and stockholder of Eli Lilly and current employee of Incyte. A.B. is a current employee and stockholder of Advaxis, Inc. J.T. reports a consulting role with Eli Lilly, Amgen, Boehringer Ingelheim, Celgene, Chugai, Imclone, Merck, Merck Serono, Millenium, Novartis, Roche, Sanofi, Symphogen and Taiho. R.G.-C., T.M., D.P. and H.O. declare no competing interests.
: This study was sponsored by Eli Lilly and Company, IN, USA.